Relapsed or Refractory B-cell Malignancies
1 clinical trials · Condition
◉ Watch Relapsed or Refractory B-cell Malignancies
| Record | Firm | Date |
|---|---|---|
| Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies (NCT06980116) | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | 2025-03-31 |
Track Relapsed or Refractory B-cell Malignancies automatically
Every clearance here is in the API, with alerts when new ones post.